Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:A61K39/42

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2023/003951COMPOSITIONS AND METHODS FOR THE TREATMENT OF HERPES SIMPLEX VIRUS INFECTION
WO 26.01.2023
Int.Class C07K 16/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
Appl.No PCT/US2022/037706 Applicant ALBERT EINSTEIN COLLEGE OF MEDICINE Inventor LAI, Jonathan, R.
Provided herein are compositions and methods for the treatment of Herpes Simplex Virus infections.
2.WO/2023/004431CHARACTERIZATION OF POTENT AND BROADLY NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST SARS-COV-2, ITS VARIANTS, AND RELATED CORONAVIRUSES AND METHODS OF USE
WO 26.01.2023
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2022/074075 Applicant THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK Inventor HO, David, D.
The subject matter described herein relates to engineered monoclonal antibodies, derived from antibodies isolated from human patients, neutralizing a SARS-CoV-2 virus, its variants, or related coronaviruses.
3.WO/2023/288078CORONAVIRUS ANTIBODIES AND USES THEREOF
WO 19.01.2023
Int.Class A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
Appl.No PCT/US2022/037330 Applicant INTERNATIONAL AIDS VACCINE INITIATIVE INC. Inventor SOK, Devin
This application provides compositions and methods for treating, preventing, or reducing the progression rate and/or severity of COVID-19, particularly treating, preventing or reducing the progression rate and/or severity of one or more COVID-19-associated complications.
4.WO/2023/287352ANTI-HBV ANTIBODIES AND USES THEREOF
WO 19.01.2023
Int.Class C07K 16/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
Appl.No PCT/SG2022/050468 Applicant NATIONAL UNIVERSITY OF SINGAPORE Inventor MACARY, Paul Anthony
The present invention relates to isolated and engineered human antibodies that specifically bind to at least one conformational (non-linear) epitope of HBsAg and neutralizes hepatitis B virus infection, method for producing the same, and uses thereof in treating human HBV infection.
5.2608978Canine parvovirus nanobody CPV-VHH-D4 and application thereof
GB 18.01.2023
Int.Class C07K 16/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
Appl.No 202216575 Applicant INST OF ANIMAL SCIENCES OF CAAS Inventor HONG JIA
A Canine Parvovirus (CPV) Nanobody CPV-VHH-D4 includes heavy chain variable region with amino acid sequence as shown in SEQ ID NO: 1, and a nucleotide sequence of a gene encoding the nanobody CPV-VHH-D4 is shown in SEQ ID NO: 2. The present application constructs a nanobody immune library for CPV by phage-display technology, and obtains specific anti-CPV nanobody CPV-VHH-D4 by screening, which is verified to specifically bind CPV through experiments, and is applicable to develop a nanobody preparation for clinical diagnosis and treatment of CPV, providing a certain theoretical support for the application of nanobodies in the field of veterinary biological products
6.0002788359THE STRAIN OF HYBRID CULTURED HOMO SAPIENS/Mus MUSCULUS CELLS Hu-C6D7-RBD IS A PRODUCER OF HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO THE RBD DOMAIN S OF THE SARS-CoV-2 VIRUS PROTEIN
RU 17.01.2023
Int.Class C12N 15/16
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
16Hormones
Appl.No 2022122661 Applicant Inventor Романенко Яна Олеговна (RU)
FIELD: health care and biotechnology. SUBSTANCE: invention relates to the field of biotechnology and medicine, in particular to a strain of hybrid cultured Homo sapiens/Mus musculus cells Hu-C6D7-RBD, a producer of human monoclonal antibodies specific to the RBD domain S of the SARS-CoV-2 virus protein. EFFECT: invention enables to expand the range of agents of human monoclonal antibodies, specific to the RBD domain S of the SARS-CoV-2 virus protein, with virus neutralizing activity, which can be used to accumulate monoclonal immunoglobulin raw materials for the subsequent production of drugs. 1 cl, 8 dwg, 9 ex
7.WO/2023/279803PROTEIN BINDING MOLECULE OF RBV AND USE THEREOF
WO 12.01.2023
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/CN2022/087557 Applicant GAO, Guang Inventor GAO, Guang
Provided is a protein molecule for preventing or treating rabies virus (RBV) infection related diseases, comprising a protein binding molecule for RBV screened by using phage display library technology. The protein molecule aims at a G protein of RBV, and the molecule contains an antibody of an immunoglobulin single variable structural domain.
8.WO/2023/279212NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2 AND USES THEREOF
WO 12.01.2023
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/CA2022/051074 Applicant VAL-CHUM, LIMITED PARTNERSHIP Inventor FINZI, Andrés
The present application discloses neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof that are effective against several SARS-CoV-2 variants. Pharmaceutical compositions comprising the antibodies or antigen-binding fragments thereof are also disclosed. The antibodies, antigen-binding fragments thereof, or pharmaceutical compositions described herein may be used for the prevention and/or treatment of coronavirus infection and/or associated diseases and symptoms, such as SARS-CoV-2 infection and/or COVID-19.
9.0002787714TEST SYSTEM BASED ON A LIQUID-PHASE BLOCKING INDIRECT SANDWICH-TYPE VARIANT OF ELISA FOR DETERMINING THE TITRE OF ANTIBODIES AGAINST THE FOOT-AND-MOUTH DISEASE VIRUS STRAIN A N2269/ARRIAH/2015, GENOTYPE A/ASIA/G-VII, IN ANIMAL BLOOD SERA AFTER IMMUNISATION
RU 11.01.2023
Int.Class A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
Appl.No 2022108324 Applicant Inventor Луговская Наталия Николаевна (RU)
FIELD: biotechnology. SUBSTANCE: invention relates to the field of veterinary virology and biotechnology. Described is a test system based on a liquid-phase blocking indirect sandwich-type variant of ELISA for determining the titre of antibodies against the foot-and-mouth disease virus strain A No.2269/ARRIAH/2015, genotype A/ASIA/G-VII, in blood sera of animals after immunisation thereof. The proposed test system contains immunospecific components, non-specific components, 4 immunological 96-well flat-bottom polystyrene ELISA plates and 1 polymer 96-well round-bottom plate. EFFECT: creation of a modern, highly specific and sensitive test system intended for determining the titre of antibodies against the foot-and-mouth disease virus strain A No.2269/ARRIAH/2015, genotype A/ASIA/G-VII. 2 cl, 4 dwg, 5 tbl, 7 ex
10.115583991B细胞表位肽及其应用和含有该B细胞表位肽的疫苗、药物组合物和检测试剂盒
CN 10.01.2023
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 202110967511.0 Applicant 北京航空航天大学 Inventor 张靖
本发明提供了一种B细胞表位肽及其应用和含有该B细胞表位肽的疫苗、药物组合物和检测试剂盒,属于生物技术领域。所述B细胞表位肽包括选自下述a)至c)的至少一种:a)、氨基酸序列为SEQ ID NO.1至SEQ ID NO.4所示的多肽中的一条或多条;b)、对氨基酸序列为SEQ ID NO.1至SEQ ID NO.4所示的多肽进行一个或多个氨基酸的插入、取代或缺失所形成的衍生多肽,所述衍生多肽具有与氨基酸序列为SEQ ID NO.1至SEQ ID NO.4所示的多肽相同或基本相同的功能;c)、由氨基酸序列为SEQ ID NO.1至SEQ ID NO.4所示的多肽中的一条或多条形成的多聚体多肽。本发明提供的B细胞表位肽具有强的免疫原性和免疫持久性,作为疫苗具有优异的抗SARS‑CoV‑2病毒能力,医用前景良好。